Subtype
Pleural Malignant Mesothelioma
CI-CAN-00001425Explore in graph →
24 active trials4 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001425Explore in graph →
Clinical trials
118 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (18)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06318286 | Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma(PENINSULA) | active not recruiting | Phase 2 | 25 | Hyogo Medical UniversityOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | active not recruiting | Phase 2 | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01064648 | Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma | active not recruiting | Phase 1 / Phase 2 | 117 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05647265 | Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma | recruiting | Phase 2 | 26 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT02535312 | Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin | active not recruiting | Phase 1 / Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05278975 | Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma | completed | Phase 1 / Phase 2 | 50 | RS Oncology LLCINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05765084 | Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma(Immuno-MESODEC) | recruiting | Phase 1 / Phase 2 | 15 | University Hospital, AntwerpOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT02399371 | Pembrolizumab in Treating Patients With Malignant Mesothelioma | completed | Phase 2 | 65 | University of ChicagoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03126630 | Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma | active not recruiting | Phase 1 / Phase 2 | 49 | National Cancer Institute (NCI)NIH | 2 | Apr 1, 2026 | clinicaltrials |
| NCT00797719 | Short Neoadjuvant Hemithoracic IMRT for MPM | completed | Phase 1 / Phase 2 | 104 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT02662504 | Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma(MesoPDT) | completed | Phase 2 | 6 | University Hospital, LilleOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT02611037 | Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma | completed | Phase 2 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 19 | CRISPR Therapeutics AGINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT04400539 | The IMmunotherapy Pleural 5-ALA PDT(IMPALA) | recruiting | Phase 2 | 20 | University Hospital, LilleOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT02863055 | Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma(NEMO) | terminated | Phase 2 | 37 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Sep 19, 2025 | clinicaltrials |
| NCT07121374 | NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study(NECIM) | recruiting | Phase 1 / Phase 2 | 37 | University Hospital, AntwerpOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT05188859 | First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma | recruiting | Phase 2 | 29 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT02649829 | Autologous Dendritic Cell Vaccination in Mesothelioma(MESODEC) | completed | Phase 1 / Phase 2 | 28 | University Hospital, AntwerpOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT01265433 | Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy | completed | Phase 2 | 41 | Sellas Life Sciences GroupINDUSTRY | 1 | Oct 9, 2024 | clinicaltrials |
| NCT05660616 | Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma | completed | Phase 2 | 40 | Ain Shams UniversityOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT04480372 | SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II | completed | Phase 2 | 68 | Swiss Cancer InstituteOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05425576 | OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition | not yet recruiting | Phase 2 | 63 | Oncotelic Inc.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT02004028 | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants | terminated | Phase 2 | 35 | Verastem, Inc.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT01486368 | A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma | completed | Phase 2 | 17 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers(REFIT-MSS) | withdrawn | Phase 2 | 0 | Translational Research in OncologyOTHER | 0 | Jun 7, 2023 | clinicaltrials |
| NCT02436733 | Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM | unknown | Phase 2 | 64 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Nov 7, 2022 | clinicaltrials |
| NCT00738582 | An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma(Amatuximab) | completed | Phase 2 | 89 | MorphotekINDUSTRY | 5 | Sep 22, 2022 | clinicaltrials |
| NCT04013334 | MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma | unknown | Phase 2 | 12 | Momotaro-Gene Inc.INDUSTRY | 1 | Jun 16, 2022 | clinicaltrials |
| NCT02347917 | A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 28 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02568449 | Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent | completed | Phase 2 | 20 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT01644994 | Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 47 | University of ZurichOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT02408016 | Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma | terminated | Phase 1 / Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT00700336 | Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) | completed | Phase 1 / Phase 2 | 69 | CanBas Co. Ltd.INDUSTRY | 1 | Jul 20, 2021 | clinicaltrials |
| NCT03213301 | Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. | completed | Phase 2 | 42 | Swiss Cancer InstituteOTHER | 2 | Jul 14, 2021 | clinicaltrials |
| NCT03786419 | A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma | withdrawn | Phase 2 | 0 | Health Pharma Professional ResearchOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT04713761 | Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma | unknown | Phase 2 | 15 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Jan 26, 2021 | clinicaltrials |
| NCT02049060 | Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin | completed | Phase 1 / Phase 2 | 31 | Armando Santoro, MDOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT03048474 | Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma(INITIATE) | completed | Phase 2 | 36 | The Netherlands Cancer InstituteOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT03177668 | Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 40 | Kissei Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 25, 2020 | clinicaltrials |
| NCT01112293 | Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma | completed | Phase 2 | 14 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT02194231 | ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)(ATREUS) | completed | Phase 2 | 145 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT03175172 | Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM) | terminated | Phase 2 | 10 | Aduro Biotech, Inc.INDUSTRY | 1 | Apr 4, 2019 | clinicaltrials |
| NCT00484276 | Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma(NGR010) | completed | Phase 2 | 57 | AGC Biologics S.p.A.INDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01358084 | Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM(NGR019) | completed | Phase 2 | 137 | AGC Biologics S.p.A.INDUSTRY | 3 | Jan 15, 2019 | clinicaltrials |
| NCT02397928 | Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) | completed | Phase 2 | 82 | NovoCure Ltd.INDUSTRY | 7 | Sep 25, 2018 | clinicaltrials |
| NCT02497508 | Nivolumab in Patients With Recurrent Malignant Mesothelioma(NivoMes) | completed | Phase 2 | 33 | The Netherlands Cancer InstituteOTHER | 0 | Sep 14, 2017 | clinicaltrials |
| NCT01721018 | Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.(1716-12) | completed | Phase 1 / Phase 2 | 12 | Virttu Biologics LimitedINDUSTRY | 1 | Jun 9, 2017 | clinicaltrials |
| NCT01869023 | Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma | unknown | Phase 2 | 26 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01211275 | Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma(N08CPA) | completed | Phase 1 / Phase 2 | 32 | The Netherlands Cancer InstituteOTHER | 1 | Feb 28, 2017 | clinicaltrials |
| NCT01870609 | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma(COMMAND) | terminated | Phase 2 | 344 | Verastem, Inc.INDUSTRY | 15 | Jan 30, 2017 | clinicaltrials |
Data updated 14 days agoSource updated Sep 16, 2026source: clinicaltrials